Market Newsdesk

Customer Demand Drives Collaboration for Global Scale, Performance and Capabilities for Privacy, Classification and Governance

RESEARCH TRIANGLE PARK, NC, Jan. 21, 2021 (GLOBE NEWSWIRE) — Data443 Risk Mitigation, Inc. (OTCPK: ATDS), the leading data security and privacy software company for ALL THINGS DATA SECURITY^™, is pleased to announce a new collaboration with the performance leader in the cloud data warehouse market – Actian Corporation.

Actian, the hybrid data management, analytics and integration company, delivers data as a competitive advantage to forward-thinking organizations around the globe that trust Actian to help them solve their toughest data challenges and transform their data into real-time business insights. With over 3,000 clients managing business critical customer data, the demand for sophisticated capabilities in data classification and data security are increasingly becoming a standard requirement for cloud or hybrid deployments.

Data443, anchored by the leading the ClassiDocs^™ data classification and governance platform will offer capabilities to the Actian solution set including:

• Over 900 exclusive data taxonomies in 14 languages
• Up-to-date data detection patterns-including U.A.E., Qatar, Saudi and Covid-19 sensitivity
• Optical Character Recognition classification engines
• Cross-platform policy-engine support for advanced platforms, including Zoom^®
• Cross-device platform support to include data from unstructured data sources including laptops and desktops

The technology and customer relationship will involve product integration, joint product marketing activities and cross-catalogue sales activities for SaaS and hybrid commercial offerings. The requirements for privacy compliance and governance management continue to require increased sophistication, performance and depth of intelligence that is available to the data owners.

“Actian customers are on a journey to the cloud and require a hybrid-cloud data warehouse solution that provides an integrated ability to identify, manage and secure sensitive data across multi-cloud platforms or in a hybrid deployment,” said Marc Potter, Chief Revenue Officer, Actian. “The partnership with Data443 and Actian provides customers with the industry’s first solution to address these requirements with zero impact on performance.”

Jason Remillard, CEO of Data443, commented, “Oncoming privacy requirements drive increased performance and capabilities. Cloud Data Warehousing is a massive marketplace and opportunity for our product set. Actian is a great company to work with, solid and respected product set and a very impressive executive leadership and board team. Their growth is an incredible story and we look forward to working with them!”

About Data443 Risk Mitigation, Inc.

Data443 Risk Mitigation, Inc. (OTCPK: ATDS), is the de facto industry leader in Data Privacy Solutions for All Things Data Security^™, providing software and services to enable secure data across local devices, network, cloud, and databases, at rest and in flight. Its suite of products and services is highlighted by: (i) ARALOC^™, which is a market leading secure, cloud-based platform for the management, protection and distribution of digital content to the desktop and mobile devices, which protects an organization’s confidential content and intellectual property assets from leakage — malicious or accidental — without impacting collaboration between all stakeholders; (ii) DATAEXPRESS^®, the leading data transport, transformation and delivery product trusted by leading financial organizations worldwide; (iii) ArcMail^™, which is a leading provider of simple, secure and cost-effective email and enterprise archiving and management solutions; (iv) ClassiDocs^™ the Company’s award-winning data classification and governance technology, which supports CCPA, LGPD, and GDPR compliance; (v) ClassiDocs^™ for Blockchain, which provides an active implementation for the Ripple XRP that protects blockchain transactions from inadvertent disclosure and data leaks; (vi) Data443^™ Global Privacy Manager^™, the privacy compliance and consumer loss mitigation platform which is integrated with ClassiDocs^™ to do the delivery portions of GDPR and CCPA as well as process Data Privacy Access Requests – removal request – with inventory by ClassiDocs^™; (vii) Resilient Access™, which enables fine-grained access controls across myriad platforms at scale for internal client systems and commercial public cloud platforms like Salesforce, Box.Net, Google G Suite, Microsoft OneDrive and others; (viii) Data443^™ Chat History Scanner, which scans chat messages for Compliance, Security, PII, PI, PCI & custom keywords; (ix) the CCPA Framework WordPress plugin, which enables organizations of all sizes to comply with the CCPA privacy framework; (x) FileFacets^®, a Software-as-a-Service (SaaS) platform that performs sophisticated data discovery and content search of structured and unstructured data within corporate networks, servers, content management systems, email, desktops and laptops; (xi) the GDPR Framework WordPress plugin, with over 30,000 active users and over 400,000 downloads it enables organizations of all sizes to comply with the GDPR and other privacy frameworks; and (xii) IntellyWP, a leading purveyor of user experience enhancement products for webmasters for the world’s largest content management platform, WordPress. For more information, please visit http://www.data443.com.

Forward-Looking Statements 

The statements contained in this release that are not historical facts are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursuant,” “target,” “continue,” and similar expressions are intended to identify such forward-looking statements. The statements in this press release that are not historical statements, including statements regarding Data443’s plans, objectives, future opportunities for Data443’s services, future financial performance and operating results and any other statements regarding Data443’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts, are forward-looking statements within the meaning of the federal securities laws. These statements are not guarantees of future performance and are subject to numerous risks, uncertainties, and assumptions, many of which are beyond Data443’s control, and which could cause actual results to differ materially from the results expressed or implied by the statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict, and include, without limitation, results of litigation, settlements and investigations; actions by third parties, including governmental agencies; volatility in customer spending; global economic conditions; ability to hire and retain personnel; loss of, or reduction in business with, key customers; difficulty with growth and integration of acquisitions; product liability; cybersecurity risk; anti-takeover measures in our charter documents; and, the uncertainties created by the ongoing outbreak of a respiratory illness caused by the 2019 novel coronavirus that was recently named by the World Health Organization as COVID-19. These and other important risk factors are described more fully in our reports and other documents filed with the Securities and Exchange Commission (“the SEC”), including under (i) “Part I, Item 1A. Risk Factors”, in our Registration Statement on Form 10 filed with the SEC on January 11, 2019 and amended on April 24, 2019; (ii) “Part I, Item 1A. Risk Factors”, in our Annual Report on Form 10-K filed with the SEC on 17 April 2020; and, (iii) subsequent filings. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Except as otherwise required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

The Data443^™ logo, ClassiDocs^™ logo, ARALOC^™ logo, DATAEXPRESS^® and FILEFACETS^® are registered trademarks of Data443 Risk Mitigation, Inc.

All product names, trademarks and registered trademarks are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks and brands does not imply endorsement.

All other trademarks cited herein are the property of their respective owners.

For Further Information:

Follow us on Twitter: https://twitter.com/data443Risk
Follow us on Facebook: https://www.facebook.com/data443/
Follow us on LinkedIn: https://www.linkedin.com/company/data443-risk-mitigation-inc/
Signup for our Investor Newsletter: https://www.data443.com/investor-relations/

Investor Relations Contact:

Matthew Abenante
[email protected]
919.858.6542

LONDON, Jan. 21, 2021 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE: GSL) (the “Company”) today announced that it has closed on its previously announced full redemption of all of the then-outstanding $233,436,000 aggregate principal amount of its 9.875% First Priority Secured Notes due 2022 (the “Notes”) at a redemption price equal to 102.469% of the principal amount thereof (the “Redemption Price”) plus accrued and unpaid interest to, but not including, the redemption date of January 20, 2021. The Company paid the Redemption Price using funds from the drawdown of its previously-announced $236.2 million senior secured loan facility with Hayfin Capital Management, LLP, along with cash on hand. All Notes have been cancelled and the Notes will no longer trade on The International Stock Exchange.

Upon the closing of the redemption, the Company issued an aggregate of 12,955,188 Class A common shares to KEP VI (Newco Marine) Ltd. and KIA VIII (Newco Marine) Ltd. (together, “Kelso”), both affiliates of Kelso & Company, a U.S. private equity firm, upon Kelso’s conversion of its 250,000 Series C Preferred Shares, representing all such shares then outstanding, in accordance with the terms of the Certificate of Designation governing the Series C Preferred Shares. Following the conversion of the Series C Preferred Shares, the Company has 30,696,196 Class A common shares outstanding.

About Global Ship Lease

Global Ship Lease is a leading independent owner of containerships with a diversified fleet of mid-sized and smaller containerships. Incorporated in the Marshall Islands, Global Ship Lease commenced operations in December 2007 with a business of owning and chartering out containerships under fixed-rate charters to top tier container liner companies. On November 15, 2018, it completed a strategic combination with Poseidon Containers.

Global Ship Lease owns 43 containerships, ranging from 2,207 to 11,040 TEU, with a total capacity of 245,280 TEU and an average age, weighted by TEU capacity, of 13.7 years as at December 31, 2020. 25 ships are Post-Panamax, of which nine are fuel-efficient new-design wide-beam.

Adjusted to include all charters agreed, and ships acquired or divested, up to January 20, 2021, the average remaining term of the Company’s charters at September 30, 2020, to the mid-point of redelivery, including options under the Company’s control, was 2.4 years on a TEU-weighted basis. Contracted revenue on the same basis was $710.0 million. Contracted revenue was $786.7 million, including options under charterers’ control and with latest redelivery date, representing a weighted average remaining term of 2.7 years.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements provide the Company’s current expectations or forecasts of future events. Forward-looking statements include statements about the Company’s expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. These forward-looking statements are based on assumptions that may be incorrect, and the Company cannot assure you that the events or expectations included in these forward-looking statements will come to pass. Actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors, including the factors described in “Risk Factors” in the Company’s Annual Report on Form 20-F and the factors and risks the Company describes in subsequent reports filed from time to time with the U.S. Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.

Investor and Media Contact:

The IGB Group
Bryan Degnan
646-673-9701
or
Leon Berman
212-477-8438

DENVER, CO, Jan. 21, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — American Cannabis Company, Inc. (OTCQB: AMMJ) (“ACC” or “Company”) is pleased to announce that it has successfully executed a non-binding letter of intent (LOI) with Andina Gold Corporation (OTCQB: AGOL) to purchase assets of its Good Meds and BOSM Labs operating division, a fully licensed cultivation and extraction operation in Colorado offering premium cannabis and cannabis extracts to the wholesale and retail medical and recreational markets. Assets are to include one cultivation operation and one hydrocarbon extraction laboratory and production center. All assets to be acquired will operate out of a 60,000-square-foot facility, centrally located in Denver, Colorado. Currently, only 50,000 square feet of space are being utilized, with 10,000 square feet of additional open space ready and available for the Company to use as it looks to scale up operations.

Since 2009, the Good Meds brand has cultivated and provided top-tier cannabis flower products to medical patients and recreational consumers in Colorado. BOSM Labs carries a strong reputation as a high-end manufacturer of well-known hydrocarbon-extracted cannabis products. Combined under one roof, these brands act as one of few long-standing and major contenders in the maturing Denver market.

Christopher Hansen, Chief Executive Officer of Andina Gold Corporation, commented: “We are pleased with the non-binding letter of intent with American Cannabis Company, and look forward to working with Terry Buffalo and his team to complete the transaction. The dedicated, consistently excellent work of Good Meds and BOSM Labs personnel has been the driver of their excellent reputation. We also appreciate the steady leadership through this transitional period provided by Amanda Price and John Haugh. We feel confident the impressive work of Good Meds and BOSM Labs will continue as we hand over the keys to American Cannabis Company.”

Terry Buffalo, Chief Executive Officer and Chief Financial Officer of American Cannabis Company, commented, “This is another strategic move for ACC. Officially having secured two non-binding LOIs to date, ACC will soon integrate three retail dispensaries and a total of 70,000 square feet of combined cultivation and extraction operations. The due diligence process for Good Meds and BOSM Labs has begun, and we anticipate this to close in Q2 of 2021. We analyzed many opportunities both here in Colorado as well as in other states, and we ultimately chose to focus on the Colorado market initially. This approach will allow us to improve existing operational processes, refine our workflow and deploy an operational management platform that we can use as we branch out to other regions of the country.”

About American Cannabis Company, Inc.

American Cannabis Company, Inc. offers end-to-end solutions to existing and aspiring participants in the cannabis and hemp industries. We utilize our industry expertise to provide business planning and market assessment services, assist state licensing procurement, create business infrastructure and operational best practices. We are continuing to grow the company by promoting our operational management services and license the American Cannabis Company brand as well as continuing to analyze acquisition opportunities worldwide. American Cannabis Company also developed and owns a portfolio of branded products including: SoHum Living Soils® – Winner of the High Times S.T.A.S.H. Award for “Best Potting Mix,” The Cultivation Cube™ and the High-Density Cultivation System™. American Cannabis Company also designs and provides other industry-specific custom product solutions.

For more information about American Cannabis Company, please visit:

www.theacclife.com

www.americancannabisconsulting.com

www.americancannabiscompanyinc.com

www.sohumsoils.com

www.americanhempservices.com

Video Links:

https://americancannabisconsulting.com/resources/video/ (ACC Site)

https://www.youtube.com/watch?v=aENC4aeNZis (High Density Cultivation System)

https://www.youtube.com/watch?v=e9rNxFph_tQ&t (Cultivation Cube)

https://www.youtube.com/watch?v=XoIcopO2yE8&t (SoHum Living Soils®)

About Good Meds

Founded in 2009, Good Meds medical cannabis dispensaries in Englewood and Lakewood, Colorado offer affordable access to premier cannabis for registered Colorado medical cannabis patients. The company’s carefully curated genetics are grown using the highest quality ingredients, to address a full spectrum of medical ailments. Good Meds generates revenue through its retail sales as well as wholesale products sold to non-Good Meds retail outlets in the recreational market. Good Meds supports the growth of the cannabis industry and abides by responsible business practices. The Good Meds assets were acquired by Andina Gold Corp. in 2019. For more information on Good Meds, please visit: https://www.goodmeds.com/.

About BOSM Labs

Serving the Colorado market since 2017, BOSM Labs balances science and art to produce quality-first, boutique extracts sold at both medical and recreational cannabis outlets. BOSM’s single-source concentrates begin with an artisan cultivation team and end with pronounced flavors that truly capture the essence of the flower at harvest. For more information on BOSM Labs, please visit: https://www.goodmeds.com/bosm-labs/.

Contact:

[email protected]

303-974-4770

[email protected]

303-222-8092

Forward-Looking Statements

This news release contains “forward-looking statements,” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”. These or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

Cannabis Remains an Illegal Schedule 1 Drug Under Federal Law

Cannabis and its derivatives are considered illegal “Schedule 1” drugs under the Controlled Substances Act (21 U.S.C. § 811). As such, Cannabis and its derivatives are viewed as being highly addictive and having no medical value. The United States Drug Enforcement Agency enforces the Controlled Substances Act, and persons violating it are subject to federal criminal prosecution. The criminal penalty structure in the Controlled Substances Act is determined based on the specific predicate violations, including but not limited to: simple possession, drug trafficking, attempt and conspiracy, distribution to minors, trafficking in drug paraphernalia, money laundering, racketeering, environmental damage from illegal manufacturing, continuing criminal enterprise, and smuggling. A first conviction under the Controlled Substances Act can generally result in possible fines from $250,000 to $50 million dollars, and incarceration for periods generally from five and up to forty years. For a second conviction, fines increase generally from $500,000 to $75 million dollars, and incarceration for periods generally from ten years to twenty years to life.

BOCA RATON, Jan. 21, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Grom Social Enterprises, Inc. (OTCQB: GRMM) (“Grom”, the “Company”, “we”, “us”, or “our”), a social media platform and original content provider for children under the age of 13, announced today that it has retained the services of New York-based investment banking firm Kingswood Capital Markets, division of Benchmark Investments, Inc. (“Kingswood”) to assist in raising new capital, as well as fund the Company’s continuing general operations.  

“The importance of the Kingswood engagement at this time cannot be overstated, as we continue to successfully execute on our growth strategies during these unprecedented, COVID-19 related times. Kingswood’s strategic influence and investment banking services will be an invaluable asset for Grom,” said Darren Marks, Grom’s Chairman and CEO. 

About Kingswood

Kingswood is a global investment bank founded by experienced investment professionals that have collectively financed over $50 billion in public and private capital markets. Our firm provides a variety of Investment Banking and Advisory services including Equity Financing, Debt Financing and Private Equity Banking. Our team is dedicated to providing objective strategic advice and financing solutions to companies across a full range of industries. For more information, please visit www.kingswoodcm.com.

About Grom Social Enterprises, Inc.

Grom Social Enterprises, Inc. (OTCQB: GRMM) is a leading social media platform and original content provider of entertainment for children under 13 years of age; providing safe and secure digital environments for kids that can be monitored by their parents or guardians. The Company has several operating subsidiaries, including Grom Social, which delivers its content through mobile and desktop environments (web portal and apps) that entertain children, let them interact with friends, access relevant news, and play proprietary games, while teaching them about being a good digital citizen. The Company owns and operates Top Draw Animation, Inc., which produces award-winning animation content for some of the largest international media companies in the world. Grom Social Enterprises also includes Grom Educational Services, which has provided web filtering services for K-12 schools, government and private business. For more information, please visit gromsocial.com.

S
afe Harbor Statement

This press release may contain forward-looking statements about Grom Social Enterprises activities that are based on current expectations, forecasts, and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues and any payment of dividends on our common stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods, and other risks set forth in the Company’s filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including, but not limited to general stock market conditions. We have incurred and will continue to incur significant expenses in the expansion of our existing and new service lines, noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long-term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations where we will be providing services, the impact of which cannot be predicted at this time. All forward-looking statements speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements or other information contained herein. Stockholders and potential investors should not place undue reliance on these forward-looking statements. Although we believe that our plans, intentions, and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved. Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

Contact:
INVESTOR RELATIONS
(561) 287-5776

GROM Social Investor Relations

TraDigital IR
Kevin McGrath
+1-646-418-7002
[email protected]

Powered by A.I., Brain E-Tattoo Technology is Expected to Provide Continuous Monitoring for Uninterrupted Data Collection in Patients with Epilepsy, Alzheimer’s, Stroke, and More.

NEW YORK, Jan. 21, 2021 (GLOBE NEWSWIRE) — via InvestorWire —

Brain Scientific
Inc. (OTCQB: BRSF) (“Brain Scientific” or the “Company”), a neurology-focused medical device and software company, has announced that it has commenced development of its proposed Brain E-Tattoo device for the brain diagnostics market, which is expected to feature a temporary implanted or imprinted minimally invasive, subcutaneous graphene electrode paired with a micro EEG. The proposed device is expected to allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions such as epilepsy, Alzheimer’s disease, stroke, and other brain disorders.

Brain Scientific is working on safety testing, general proof of concept testing and performance testing for the Brain E-Tattoo device, prior to FDA submission.

Brain Scientific’s proposed Brain E-Tattoo device is being designed to monitor brain wave activity beyond the clinical setting, with no or minimal impact to the patient’s daily life. The Brain E-Tattoo’s graphene-based electrodes would be connected to the micro EEG clipped behind the ear, which processes the signals from the sensors and wirelessly transfers data to a cloud application. Each patient’s data is secured in the cloud where Brain Scientific’s artificial intelligence performs continuous analysis. Brain Scientific expects that the device will provide researchers with an affordable option to monitor, study, and continue research for numerous neurological disorders, including epilepsy, one of the most common chronic brain diseases. For epileptic patients and others facing neurological diseases, Brain Scientific hopes that the continued analysis and AI prediction will lead to a better understanding of neurological disorders.

“Our current EEG device is about the size of a stamp. By shrinking the technology, the system allows for continuous measurement during a person’s normal activities, while providing a non-intrusive way to monitor various disorders,” said Boris Goldstein, Chairman of Brain Scientific. We believe the future of EEG testing will be centered around the ability to gather more precise data through non-invasive measures of the brain via 3D temporary imprint or implanted graphene electrodes. By utilizing graphene, which has been called a “wonder material of the 21st century”, Brain Scientific believes the size of the electrodes can be thinner than a human hair and will allow brain activity monitoring with minimal distraction from everyday life.”

Brain Scientific filed a patent application in the United States Patent and Trademark Office (USPTO) for the Brain E-Tattoo device, entitled “INTEGRATED BRAIN MACHINE INTERFACE PLATFORM WITH GRAPHENE BASED ELECTRODES” in 2020. Upon commercialization, the Brain E-Tattoo device would join Brain Scientific’s lineup of highly advanced brain monitoring products, which includes the disposable EEG caps NeuroCap™ and NeuroCap-Pediatric, and the portable, compact and wireless NeuroEEG amplifier for routine EEG monitoring. These disposable technologies are also designed to provide clinicians with low cost, timely, and safe EEG testing options.

The ongoing global pandemic has highlighted the urgent need for clinicians to minimize contact with patients, while providing important testing such as brain scans. Studies show that more than 80% of hospitalized COVID-19 patients have neurological symptoms, which could require EEG testing. Brain Scientific believes that its technology is providing safer alternatives in testing, and the Brain E-Tattoo technology will continue to provide these advancements and to bring new innovative norms to clinicians around the globe. Additionally, the past year has brought a significant amount of attention to developments in brain implants from the likes of Elon Musk’s NeuraLink Corporation and others.

The Company was selected as a finalist at the 2020 Epilepsy Foundation Shark Tank Competition and presented this idea at the Pipeline Conference, held virtually on August 27, 2020.

To learn more about Brain Scientific, visit www.brainscientific.com, and watch the Brain E-Tattoo in action.

About Brain Scientific

Brain Scientific
is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The Company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about our corporate strategy, devices or for investor relations please visit: www.brainscientific.com or email us at [email protected].

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek” or “project” or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates, and assumptions, and are subject to several risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand its business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company’s raw materials, the Company’s failure to develop any of its product candidates or technologies, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company does not undertake to update these forward-looking statements.

Photos: (Credits:
MAKinteract Lab, Department of Industrial Design, KAIST, South Korea)

https://photos.google.com/share/AF1QipOWNDzDK1yzW9YsWojb3DkTYRitcpAHUXZhVyj1YoaJnGfIEfHfQDMAFnDvizn36Q?key=U3RyanlmbTVkQ3VFSExiNl9pb2diR1JDWFBWTE1B

Video:

https://www.youtube.com/watch?v=iYj47TvEIfM&feature=youtu.be

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/44262f9e-0792-4ee9-ad49-cc07805cc562

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e8412523-8f47-4348-aa2f-95b03b6acd4f

PHOENIX, AZ, Jan. 21, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Today American Green (ERBB:OTC) announces that the Company’s launch on Amazon of their exclusive line of specialty HempCream was a success. “We had our official Amazon Store Grand Opening on December 17th and we could not be happier with the positive response we received from our Amazon-based customers.  We sold out of all 4 scents (Citrus, Lavender, Peppermint and Plain-Hypo-allergenic) within the first day of launching,” said David Gwyther, American Green’s president.

According to American Green’s Online Sales VP, Kevin Davis, “Since our Amazon Grand Opening, our company has been able to timely restock our supply, allowing us to fulfill all of our Hemp Cream orders we received,” says Davis. “The Company has also added Amazon Prime to its offerings where our popular products like our Hemp Cream will be fulfilled directly by Amazon with free 2-day shipping for Amazon Prime members.”

American Green leverages Amazon’s expertise when it comes to predicting future demand of its products. Our growing customer base can always count on American Green to constantly refine and improve our fulfillment process to assure that our hemp product line is always of the highest quality and delivered on time.

Through customer feedback, customers were delighted to hear that our Plain Hemp Cream is now hypoallergenic and offered to the public only samples of each product are independently lab-tested and certified.  “It’s evident that using Amazon as a strategic partner in 2021 will allow us to reach new customers, increase our sales, and capitalize on the burgeoning Hemp Market, as we nurture new customers and opportunities on the world’s largest retail giant,” concludes Mr. Davis.

Exclusive Amazon Pricing Extended

To ensure we reach every customer, we have extended our special price of $44.95 on our Hemp Creams, thru January 31st.

Readers can view our entire catalog which features our Hemp Creams in addition to our apparel by visiting amazon.com/americangreen.

Shareholders and interest holders may also stay current with American Green Updates:

American Green’s Main Website at www.americangreen.com

Twitter:  @American__Green (two underscores), or

Facebook:      https://www.facebook.com/americangreenusa

Instagram:      https://www.instagram.com/americangreenusa/

Instagram:      https://www.instagram.com/magicalnipton/

About American Green, Inc.

In 2009,

American Green, Inc.
became America’s second publicly-traded company in the cannabis sector. American Green now, with its more than 50,000 certified beneficial shareholders, is one of the largest (in shareholder count) in the cannabis sector.  American Green’s mission is to lead the cannabis and premium CBD industry. Leveraging our team of professionals in cultivation management, manufacturing, extraction, wholesale, retail, and community outreach, we strive to develop sustainable initiatives in the cannabis-adjacent and CBD industries, laser-focused on adding company and shareholder value.

For more information –

Contact:

American Green, Inc.

Investor Relations

2902 W. Virginia Ave

Phoenix, AZ  85009

480-443-1600 X555

[email protected]

NOTES ABOUT FORWARD-LOOKING STATEMENTS

Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company’s Securities and Exchange Commission reports and filings. Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, be should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made.

TORONTO, CHICAGO and MONTREAL, Jan. 21, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has submitted its application to list on The Nasdaq Capital Market® (the “Nasdaq”).

Ken d’Entremont, Chief Executive Officer of Medexus, commented, “The submission of our application to list on the Nasdaq marks a significant milestone for Medexus. We believe we now meet the initial listing requirements, which reflects the success of our ongoing efforts to create a highly scalable business platform with a diversified and growing product portfolio across North America. In fact, we have grown at a 129% CAGR over the past 3 fiscal years alone and are generating very strong cash flow. Given our current trajectory and growth of our U.S-based business that now accounts for more than 74% of total revenues, management and the board of directors are actively working to complete all of the necessary steps to successfully complete the proposed dual listing on Nasdaq. We believe a listing in the U.S. would provide us much greater exposure within the investment community as we execute on key upcoming financial and operational milestones. Our application is currently under review with Nasdaq staff and we intend to provide further updates as developments unfold.”

The listing of the Company’s common shares on the Nasdaq remains subject to the approval of the Nasdaq and the satisfaction of all applicable listing and regulatory requirements. While the Company intends to satisfy all of the applicable listing criteria, no assurance can be given that its application will be approved. The Company plans to maintain its current listing on the TSX Venture Exchange and on the Frankfurt Stock Exchange.

Investor Update Webinar

The Company is also announcing today that Ken d’Entremont, CEO, and Roland Boivin, CFO will host an Investor Update Webinar on January 25th, 2021 at 2:00 PM Eastern Time to provide an operational update, followed by a question-and-answer period.

Registration Link: Medexus Pharmaceuticals Investor Update

After registering, you will receive a confirmation email containing information about joining the webinar. Questions may be asked during the webinar or can be emailed in to [email protected]. A replay will be made available on the Medexus website.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative allergy medication with a unique mode of action.

For more information, please contact:

Ken d’Entremont, Chief Executive Officer
Medexus Pharmaceuticals Inc.
Tel.: 905-676-0003
E-mail: [email protected]

Roland Boivin, Chief Financial Officer
Medexus Pharmaceuticals Inc.
Tel.: 514-344-8765
E-mail: [email protected]

Investor Relations (U.S.):
Crescendo Communications, LLC
Tel: +1-212-671-1020
Email: [email protected]

Investor Relations (Canada):
Tina Byers
Adelaide Capital
Tel: 905-330-3275
E-mail: [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). The words “anticipates”, “believes”, “expects”, “will”, “plans” and similar expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Specific forward-looking statements contained in this news release include, but are not limited to, statements with respect to the Company’s ability to list on the Nasdaq, the benefits to the Company associated with such a listing on the Nasdaq and the Investor Update Webinar. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include those set out in the Company’s materials filed with the Canadian securities regulatory authorities from time to time, including the Company’s most recent annual information form and management’s discussion and analysis; future capital requirements and dilution; intellectual property protection and infringement risks; competition (including potential for generic competition); reliance on key management personnel; the Company’s ability to implement its business plan; the Company’s ability to leverage its United States and Canadian infrastructure to promote additional growth, including with respect to the infrastructure of Medexus Inc. and Medac Pharma, Inc. and the potential benefits the Company expects to derive therefrom; regulatory approval by the Canadian health authorities; product reimbursement by third party payers; patent litigation or patent expiry; litigation risk; stock price volatility; government regulation; and potential third party claims. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of the date hereof. Other than as specifically required by law, the Company undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.

 

– 3

^rd

Limited Edition in Six Months Using Themed Label Images to Drive Growth –

SEATTLE, Jan. 21, 2021 (GLOBE NEWSWIRE) — Jones Soda Co. (OTCQB: JSDA), the original craft soda known for its unconventional flavors and user-designed label artwork, is paying tribute to some of 2020’s most inspiring private citizens with a limited-edition, eight-bottle “Unsung Heroes” collection hitting store shelves this month. The campaign is the latest in a series of themed releases that are successfully using the company’s unique label-based brand personality to invigorate sales.

The new Unsung Heroes collection features photographs of various people or groups who took extraordinary steps to help others during a difficult year. Examples include a small California restaurant that provided hundreds of meals to the 2020 Glass Fire evacuees and first responders, a firefighter at the Skyxe Saskatoon International Airport, and a nonprofit organization that has delivered 55-gallon barrels of clean, potable drinking water to remote areas of the Navajo Nation since the COVID-19 pandemic began. The series is appearing on Jones Green Apple Soda bottles in both the U.S. and Canada with a total print run of 500,000. All eight honorees are profiled at www.jonessoda.com/unsung-heroes.

In addition, consumers can use Jones’ popular custom label program to order personalized bottles spotlighting the unsung heroes in their own lives, complete with the Unsung Heroes logo and the uploaded photo of their choice. They also can nominate their personal unsung hero by submitting a photo to the Jones photo gallery for possible inclusion on a future Jones bottle.

The campaign joins a marketing reboot that began last summer with a “Messages of Hope” collection featuring images of positivity during the pandemic and continued with a “Vote 2020” series which included QR codes that turned Jones Cream Soda bottles into two-minute voter registration tools. Additional themed series are planned throughout 2021.

These renewed marketing investments, which also included a high-profile RV campaign last July featuring legendary skateboarder Tony Hawk, are part of a strategic growth plan that helped the company achieve a 17% year-over-year revenue increase and improved gross margins in the third quarter of 2020.

“The themed collections we introduced in 2020 created an emotional connection with consumers by leveraging one of our most valuable brand assets – constantly changing label images submitted by Jones fans – to address some of the most urgent issues of the day,” said Mark Murray, Jones Soda President and CEO. “These collections raised our brand profile, garnered thousands of new followers and millions of social media impressions, and helped deliver a strong Q3 that continued into Q4. Our new Unsung Heroes campaign is the first of a series of initiatives we are implementing to sustain and accelerate that growth in 2021, building on the innovative flavors and labels ‘of the people and for the people’ that have distinguished the brand for 25 years.”

About Jones Soda Co.

Headquartered in Seattle, Washington, Jones Soda Co.^® (OTCQB: JSDA) markets and distributes premium beverages under the Jones^® Soda and Lemoncocco^® brands. A leader in the premium soda category, Jones Soda is made with cane sugar and other high-quality ingredients, and is known for packaging that incorporates ever-changing photos sent in from its consumers. Jones’ diverse product line offers something for everyone – cane sugar soda, zero-calorie soda and Lemoncocco non-carbonated premium refreshment. Jones is sold across North America in glass bottles, cans and on fountain through traditional beverage outlets, restaurants and alternative accounts. For more information, visit www.jonessoda.com or www.myjones.com or www.drinklemoncocco.com.

Media Relations Contact

Jim Capalbo
JSPR
[email protected]

Investor Relations Contact

Cody Slach or Cody Cree
Gateway Investor Relations
1-949-574-3860
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7b3d0445-31d0-4de7-ab5c-c4163c68a6ff

Clinical trial will utilize a single-protocol Phase 1/2/3 design

UX701 manufacturing complete at commercial quality and scale using HeLa PCL technology

First patient to be dosed in the first half of 2021

NOVATO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for UX701, an investigational AAV9 gene therapy being evaluated for the treatment of Wilson Disease. Enrollment in a seamless single-protocol Phase 1/2/3 study is expected to begin in the first half of 2021. This will be the company’s third in-house clinical gene therapy program and the second program in the clinic with the HeLa producer cell line manufacturing system.

“FDA IND clearance allows for the advancement of this new gene therapy into the clinic and brings forward the hope for a new treatment for patients with Wilson Disease. UX701 has the potential to directly address the underlying basis of disease by restoring the normal transport and excretion of copper,” said Eric Crombez, M.D., Chief Medical Officer of the Ultragenyx Gene Therapy development unit. “The seamless Phase 1/2/3 clinical trial design will allow us to efficiently evaluate safety and efficacy of UX701 before studying an optimal dose in a larger number of patients to support registration. We appreciate the agency’s support for a novel clinical trial design that could bring this important potentially new treatment to the greatest number of patients as efficiently as possible.”

Study Design

UX701 will be studied in a seamless, single-protocol Phase 1/2/3 clinical trial. Manufacture and testing of GMP-grade drug product to supply the clinical study are complete using the company’s proprietary HeLa 2.0 producer cell line (PCL) process at the 2,000 liter scale.

Stage 1 (
evaluation of initial safety and dose finding
)

In the first stage of the study, the safety and efficacy of three dose levels of UX701 will be evaluated in 27 patients (nine per cohort), randomized 2-to-1 (gene therapy versus placebo). The dose cohorts will be enrolled sequentially using ascending doses. The patients will be followed for 52 weeks before transitioning to long-term follow-up and selecting a pivotal dose. The dose will be determined based on the safety profile, changes in biomarkers of copper metabolism (e.g. 24-hr urinary copper, ceruloplasmin concentration, ceruloplasmin activity, non-ceruloplasmin bound copper, and total serum copper), and the reduction in the use of the current standard (SOC), copper chelator and/or zinc.

Stage 2 (
optimal dose evaluation for pivotal clinical data generation
)

The second and pivotal stage will use the dose selected from Stage 1 and enroll an additional 63 patients, randomized 2-to-1 (gene therapy versus placebo). The co-primary endpoints in Stage 2 will evaluate the effect of UX701 on copper regulation based on 24-hour urinary copper concentration and percent reduction in SOC at Week 52. Key secondary endpoints in Stage 2 include the effect of UX701 on additional biomarkers of copper metabolism and patient- and clinician-reported outcomes from a modified Wilson Disease Functional Rating Scale.

Stage 3 (long-term follow-up)

All patients in Stage 1 and Stage 2 who are randomized to receive placebo may be eligible to receive UX701 at the Stage 2 dose. Patients receiving UX701 will be continued to be monitored for long term safety and durability of response.

About Wilson Disease

Wilson disease is a rare inherited disorder caused by mutations in the ATP7B gene, which results in deficient production of ATP7B, a protein that transports copper. Loss of function of this copper-binding protein results in the accumulation of copper in the liver and other tissues, most notably the central nervous system. Patients with Wilson disease experience hepatic, neurologic and/or psychiatric problems. Those with liver disease can experience such symptoms as fatigue, lack of appetite, abdominal pain and jaundice, and can progress to fibrosis, cirrhosis, life-threatening liver failure and death. Wilson disease can be managed by reducing copper absorption or removing excess copper from the body using life-long chelation therapy, but unmet needs exist because some treated patients experience clinical deterioration and debilitating side effects. Wilson disease affects more than 50,000 individuals in the developed world.

About UX701

UX701 is an investigational AAV type 9 gene therapy designed to deliver stable expression of a truncated version of the ATP7B copper transporter following a single intravenous infusion. It has been shown in preclinical studies to improve copper distribution and excretion from the body and reverse pathological findings of Wilson liver disease. UX701 was granted Orphan Drug Designation in the United States and European Union.

About Ultragenyx

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements related to Ultragenyx’s expectations and projections regarding its future operating results and financial performance, anticipated cost or expense reductions, the timing, progress and plans for its clinical programs and clinical studies, future regulatory interactions, and the components and timing of regulatory submissions are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, collaboration with third parties, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the effects from the COVID-19 pandemic on the company’s clinical activities, business and operating results, risks related to reliance on third party partners to conduct certain activities on the company’s behalf, uncertainty and potential delays related to clinical drug development, smaller than anticipated market opportunities for the company’s products and product candidates, manufacturing risks, competition from other therapies or products, and other matters that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations, the company’s future operating results and financial performance, the timing of clinical trial activities and reporting results from same, and the availability or commercial potential of Ultragenyx’s products and drug candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 27, 2020, and its subsequent periodic reports filed with the Securities and Exchange Commission.

Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-660-0951